Метаболический эффект гормона ростапри гипопитуитаризме у взрослых

Обзор освещает основные метаболические нарушения, характерные для взрослых пациентов с гипопитуитаризмом
(ГП), которые зачастую невозможно решить с помощью традиционной заместительной гормональной терапии.
Положительное влияние терапии рекомбинантным гормоном роста (рГР) доказало необходимость ее применения у этих па-
циентов. Комплексное замещение всех тропных недостаточностей, включая соматотропный гормон (СТГ), позволяет орга-
низму работать в условиях гормонального обмена, максимально приближенного к нормальному, полностью нивелируя
или сводя к минимуму последствия метаболических нарушений, характерных для взрослых с ГП.

гипопитуитаризм, сердечно-сосудистые заболевания, состав тела, инсулинорезистентность, гормон роста

1. Дедов И.И., Тюльпаков А.Н., Петеркова В.А. Соматотропная недостаточность. Москва, «ИндексПринт». 1998.

2. Amato G., Carella C., Fazio S. Body composition, bone metabolism and heart structure and function in growth hormone (GH) deficient adults before and after GH replacement therapy // J. Clin. Endocrinol. Metab. 1993, 77: P. 1671-1676.

3. Attanasio A., Mo D., Erfurth E. Prevalence of metabolic syndrome in adult hypopituitarism growth hormone (GH)-deficient patient before and after GH replacement // J. Clin. Endocrinol. Metab. 2009, 95: P. 74-81.

4. Attanasio A., Lamberts S., Matranga A. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onest and adult onest before and during human GH treatment // J. Clin. Endocrinol. Metab. 1997,82(1): P. 82-88.

5. Attanasio A., Lamberts S., Matranga A. Adult growth hormone (GH)-deficient patients demonstrate heterogeneity between childhood onset and adult onset before and during human GH treatment // J. Clin. Endocrinol. Metab. 1997, 82(1): P. 82-88.

6. Bengtsson B., Abs R., Bennmarker H. The effects of treatment and the individual responsiveness to growth hormone (GH) replacement therapy in 665 GH-deficient adults // J. Clin. Endocrinol. Metab. 1999, 84(11): P. 3929-3935.

7. Beshyah S., Freemantle C., Thomas E. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults // J. Clin. Endocrinol. Metab. 1995, 42: P. 178-189.

8. Beshyah S., Shahi M., Mayet J. Growth hormone and the cardiovascular system. (eds. Ranke M), 1996, P. 131-155. J and J-Verlag, Mannaheim.

9. Beznak M. The restoration of cardiac hypertrophy and blood pressure in hypophysectomised rats by large doses of lyophilized anterior pituitary and growth hormone // J. Physiology. 1954, 124: P. 64-74.

10. Binnerts A., Swart G., Wilson J. The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as body composition // J. Clin. Endocrinol. 1992, 37: P. 79-87.

11. Binnerts A., Deurenberg P., Swart G. Body composition in growth hormone-deficient adults // Am. J. Clin. Nutr. 1992, 55: P. 918-923.

12. Boschetti M., Goglia U., Teti C. Replasement therapy and cardiovascular disease // J. Endocrinol. Invest. 2008, 31(9 Suppl): P. 85-90.

13. Bozzola M., Tettoni K., Severi F. Does growth hormone treatment increase chromosomal abnormalities? // J. Clin. Endocrinol. (Oxf). 1997, 47: P. 363-366.

14. Bulow B., Hagmar L., Mikoczy Z. Increased cerebrovascular mortality in patients with hypopituitarism // J. Clin. Endocrinol. Metab. 1997, 46: P. 75-81.

15. Burman P., Johansson A., Siegbahn A. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than woman // J. Clin. Endocrinol. Metab. 1997, 82: P. 550-555.

16. Burman P., Johansson A., Siegbahn A. Growth hormone (GH)-deficient men are more responsive to GH replacement therapy than women // J. Clin. Endocrinol. Metab.1997 Feb., 82(2): P. 550-555.

17. Capaldo B., Patti L., Oliviero U. Increased arterial intima-media thickness in childhood- onset growth hormone deficiency // J. Clin. Endocrinol. Metab. 1997, 82: P. 1378-1381.

18. Chrisoulidou A., Beshyah S., Rutherford O. Effects of 7 year of growth hormone replacement therapy in hypopituitary adults // J. Clin. Endocrinol. Metab. 2000, 85(10): P. 3762-3769.

19. Christopher M., Hew F., Oakley M. Defects of insulin action and skeletal muscle glucose metabolism in growth hormone-deficient adults persist after 24 months of recombinant human growth hormone therapy // J. Clin. Endocrinol. Metab. 1998 May, 83(5): P. 1668-1681.

20. Cittadini A., Cuacolo A., Merola B. Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement // J. Physiology. 1994, 267: E219-E225.

21. Colao A., di Somma C., Cuocolo A. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adults patients with GH deficiency // J. Clin. Endocrinol. Metab. 2001, 86: P. 1874-1881.

22. Conceicao F., Jorgensen J., Vahl N. Evidence-based approach to growth hormone replacement therapy in adults,with special emphasis on body composition // J. Pediatr. Endocrinol. Metab. 2000, 13(Suppl 6): P. 1353-1358.

23. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society Workshop on adult hormone deficiency // J. Clin. Endocrinol. Metab. 1998, 83: P. 379-381.

24. Davies J., Obuobie K., Smith J. A therapeutic trial of growth hormone in hypopituitary adults and its influence upon continued prescription by general practitioners // Clin. Endocrinol. (Oxf.). 2000, 52: P. 295-303.

25. Drake W., Rodriguez-Arnao J., Weaver J. The influence of gender on the short and long-term effects of the growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-years study // Clin. Endocrinol. (Oxf). 2001, 54: P. 525-532.

26. Dunne F., Elliot P., Gammage M. Cardiovascular function and glucocorticoid replacement in patients with hypopituitarism // J. Clin. Endocrinol. Metab.1995, 43: P. 623-629.

27. Fernholm R., Bramnert M., Hagg E. Growth hormone replacement therapy improves body composition and increases bone metabolism in eidery patients with pituitary disease. J. Clin. Endocrinol. Metab. 2000, 85: P. 4104-4112.

28. Gibney J., Johannsson G. Safety of growth hormone replacement therapy in adults // Expert. Opin. Drug. Saf. 2004, 3: P. 305-316.

29. Graham M., Evans P., Thomas N. Changes in endothelial dysfunction and assotiated cardiovascular disease morbility markers in GH-IGF axis pathology // Am. J. Cardiovasc. Drugs. 2009, 9: P. 371-381.

30. Hansen T., Vahl N., Jorgensen J. Whole body and regional soft tissue changes in growth hiormone deficient adults after one year of growth hormone treatment: a double-blind, randomized, plecebo-controlled study // Clin. Endocrinol. (Oxf). 1995, 43: P. 689-696.

31. Hirsch E., Sloman J., Vartin F. Cardiac function in acromegaly // J. Medical Science. 1969, 257: P. 1-8.

32. Hjalmarson A., Isaksson O., Ahren K. Effect of growth hormone and insulin on amino acid transport in perfused rat heart // J. Physiology. 1969, 217: P. 1795-1802.

33. Janssen J., van Der Toorn F., Hofland L. Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy // Eur. J. Endocrinol. 2001, 145: P. 711-716.

34. Johansson A. Gender difference in growth hormone response in adults // J. Endocrinol. Invest. 1999, 22 (Suppl 5): P. 58-60.

35. Johansson A. Gender difference in growth hormone response in adults // J. Endocrinol. Invest. 1999, 22 (Suppl 5): P. 58-60.

36. Johansson J., Oscarsson J., Bjarnason R. Two weeks of daily injections and continuous infusion of recombinant human growth hormone (GH) in GH-deficient adults: efftcts on insulin-like growth factor-I (IGF-I), GH and IGF binding proteins, and glucose homeostasis // J. Metabolism. 1996, 45: P. 352-359.

37. Jorgensen J., Pedensen S., Thuesen L. Beneficial effects of growth hormone treatment in growth hormone deficient adults // J. Lancet. 1989, 1: P. 1221-1225.

38. Kehely A., Birkett M., Weatherall R. The hypopituitary control and complications study (HypoCCS): baseline data // Topical Endocrinol. 1999, (Suppl. 5), P. 1-28.

39. Lissett C., Shalet S. Effects of growth hormone on bone and muscle // Growth horm IGF Res. 2000, 10 Muscles: S95-S101.

40. Longobardi S., Cuacolo A., Merola B. Left ventricular function in young adults with childhood and adulthood anset growth hormone deficiency // J. Clin. Endocrinol. Metab.1998, 48: P. 137-144.

41. Markussis V., Beshyah S., Fisher C. Abnormal carotid wall arterial wall dynamics in symptom-free hypopituitary agults // Eur. J. of Endocrinology. 1997, 136: P. 157-164.

42. Marta P., Rogol A., Veldhuis J. Alteration in the pulsatile properties of circulating GH concentration during puberty in boys // J. Clin. Endocrinol. Metab. 1989, 69: P. 563-570.

43. Matsumura K., Abe I., Fukuhara M. Madulation of circadian rhythm of blood pressure by cortisol in patients with hypopituitarism // J. Clin. Exper. Hypertansion. 1994, 16: P. 55-66.

44. Merola B., Cittadini A., Colao A. Cardiac structural and functional abnormalities in adults patients with growth hormone deficiency // J. Clin. Endocrinol. Metab. 1993, 77: P. 1658-1661.

45. Mukhejee A., Shalet S. The value of IGF1 estimation in adults with GH deficiency // Eur. J. Endocrinol. 2009, 161 Suppl.

46. Mukherjee A., Murray R., Shlet S. Impact of growth hormone status on body composition and the skeleton // Horm. Res. 2004, 62 Suppl 3: P. 35-41.

47. Olivecrona H., Johansson A., Lindh E. Hormonal regulation of serum lipoprotein (a) levels: contrasting effects of growth hormone and insulin like growth factor-I // J. Arteriosclerosis, Thrombosis and Vascular Biology. 1995, 15: P. 847-849.

48. Roemmler J., Kuenkler M., Schneider H. Cjmparison of glucose and lipid metabolism and bone mineralization in patients with growth hormone deficiency with and without long-term growth hormone replasement // J. Metabolism. 2010, 59: P. 350-358.

49. Rosen T., Bengtsson B. Premature mortality due to cardiovascular disease in hypopituitarism // J. Lancet. 1990, 336: P. 285-288.

50. Russell-Jones D., Watts G., Weissberger A. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adults growth hormone deficient patients // J. Clin. Endocrinol. 1994, 41: P. 345-350.

51. Salomon F., Cuneo R., Hesp R. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency // N. Engl. J. Med. 1989, 321: P. 1719-1803.

52. Shahi M., Beshyah S., Hackett D. Myocardial dysfunctional in treated adult hypopituitarism: a possible explanation for increased cardiovascular mortality // British Heart J. 1992, 67: P. 92-96.

53. Shoumer K., Gray R., Anyaoku V. Effects of four years treatment with biosinthethic human growth hormone (GH) on glucose homeostasis, insulin secrecion and lipid metabolism in GH-deficient adults // Clin. Endocrinol. 1998, 48: P. 795-802.

54. Smith R., Thorner M. Human growth hormone: research and clinical practice // Humana Press Totowa New Jersey. 2000, P. 221-228.

55. Snel Y., Brummer R., Doerga M. Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: the effect of growth hormone replacement and comparison with control subjects // American. J. of Clinical Nutrition. 1995. 61: P. 1290-1294.

56. Sneppen S., Hoeck H., Kollerup G. Bon mineral content and bone metabolism during physiological GH treatment in GH-deficient adults. An 18-month randomised. Placebocontrolled, double blinded trial // Eur. J. of Endocrinol. 2002, 146(2): P. 187-195.

57. Vahl N., Jorgensen J., Hansen T. The favourable effect of growth hormone (GH) substitution hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12 month placebo-controlled study // Int. J. Obes. Relat. Metab. Disord. 1998, 22: P. 529-536.

58. Valcavi R., Gaddi O., Zini M. Cardiac performance and mass in adults with hypopituitarism: effect of one year of growth hormone treatment // J. Clin. Endocrinol. Metab. 1995, 80: P. 659-666.

59. Valce M., Mauras N. Growth hormone therapy in adults and children // The New Engl. J. of Medicine. 1999, 341: P. 1206-1216.

60. Verhelst J., Abs R. Cardiovascular risk factors in hypopituitary GH-deficient adults // Eur. J. Endocrinol. 2009, 161 Suppl.

61. Weaver J., Manson J., Noonan K. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity and cardiovascular risk factors in hypopituitary adults // J. Clin. Endocrinol. Metab. 1995. 80: P. 153-159.

62. Wolthers T., Hoffman D., Nugent A. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient woman // Am. J. Phisiol. Endocrinol. Metab. 2001, 281: E1191-1196.

63. Wuster C., Abs R., Bengtsson B. The KIMS Study Group and the KIMS International Board. Pharmacia & Upjohn International Metabolic Detabase. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density // J. Bone Miner. Res. 2001,16: P. 398-405.